Sequenom Inc. (SQNM) said that it has entered into an collaboration with the Immune Tolerance Institute Inc. to develop an advanced newborn screening test for severe combined immunodeficiency based on the pioneering work of Jennifer Puck of the University of California, San Francisco.
A successful feasibility study was recently completed demonstrating the adaptability of Dr. Puck's RT-PCR screening assay for SCID diagnosis on the MassARRAY platform developed by Sequenom.
Sequenom noted that its proprietary MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein.
For comments and feedback: editorial@rttnews.com